Is Hong Kong's New World Too Big to Fail?
The real estate developer's systemic importance is of great concern to residents, policymakers and investors alike. Property fire sales at New World could drag down home prices further, while a potential default will impair banks' loan books. But for the company's $4.5 billion perpetual bond holders, there's a possible happy ending if the builder is deemed too big to fail: An equity injection from Chinese state-owned enterprises or the Hong Kong government would make their day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Siemens Healthineers AG (ETR:SHL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 2.0% to hit €5.7b. Siemens Healthineers reported statutory earnings per share (EPS) €0.49, which was a notable 17% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 18 analysts covering Siemens Healthineers are now predicting revenues of €24.6b in 2026. If met, this would reflect a modest 5.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 17% to €2.29. In the lead-up to this report, the analysts had been modelling revenues of €24.8b and earnings per share (EPS) of €2.34 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. See our latest analysis for Siemens Healthineers The consensus price target held steady at €59.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Siemens Healthineers, with the most bullish analyst valuing it at €65.00 and the most bearish at €50.00 per share. This is a very narrow spread of estimates, implying either that Siemens Healthineers is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Siemens Healthineers' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Siemens Healthineers. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Siemens Healthineers. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Siemens Healthineers going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
36 minutes ago
- Yahoo
Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Siemens Healthineers AG (ETR:SHL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 2.0% to hit €5.7b. Siemens Healthineers reported statutory earnings per share (EPS) €0.49, which was a notable 17% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 18 analysts covering Siemens Healthineers are now predicting revenues of €24.6b in 2026. If met, this would reflect a modest 5.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 17% to €2.29. In the lead-up to this report, the analysts had been modelling revenues of €24.8b and earnings per share (EPS) of €2.34 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. See our latest analysis for Siemens Healthineers The consensus price target held steady at €59.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Siemens Healthineers, with the most bullish analyst valuing it at €65.00 and the most bearish at €50.00 per share. This is a very narrow spread of estimates, implying either that Siemens Healthineers is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Siemens Healthineers' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Siemens Healthineers. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Siemens Healthineers. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Siemens Healthineers going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
What's going on with the Card Factory share price?
On several occasions, I've suggested that the Card Factory (LSE:CARD) share price was depressed or beaten down because the market didn't like its limited online presence. However, that's now changing with the acquisition of Funky Pigeon from WH Smith. The £24m purchase marks a major strategic shift, addressing long-standing concerns over its minimal online presence. Funky Pigeon will deliver a mature digital platform, experienced technology teams, and established direct-to-recipient gifting capabilities, enhancing Card Factory's digital proposition. The former WH Smith brand has been operating a successful business with average annual revenues around £32m and EBITDA of around £5m over the last two years. Cross-selling opportunities, operational efficiencies, and access to richer customer data should follow. Ultimately, this move positions Card Factory to become a top omni-channel player, uniting over 1,000 stores with a competitive online offer. Shares surge The share price surged after the acquisition was announced. Clearly, investors were happy to see the business make more progress in expanding its digital presence. However, the stock's valuation certainly isn't too demanding. The company's now trading at 6.1 times forward earnings and it's expected to have a net debt position of around £116m by the end of the year. This forward price-to-earnings (P/E) ratio's expected to fall to 5.4 times by 2027. In fact, earnings may even accelerate faster than this, given the Funky Pigeon takeover. Remember, analysts don't always update their forecasts immediately. The dividend yield remains sizeable despite the rise — share prices and dividend yields are inversely correlated. The forward yield currently sits at 6% and is expected to rise to around 7% by 2027. That's based on today's share price and the dividend forecast. It's also worth noting that dividend coverage is strong at almost three times. This suggests the payments are sustainable even if the business falls on hard times. The bottom line Card Factory, for now, remains a traditional retailer with a distinct brand and deep ties to celebrations and everyday moments. This is a quality that helps it weather shifts in consumer sentiment. The business has shown agility, adapting products and store formats to remain relevant on high streets across the UK. Seemingly, customer loyalty remains strong due to its value proposition and broad selection. While the acquisition of Funky Pigeon offers new digital potential, Card Factory's core challenge remains revitalising its high street presence and ensuring that physical stores complement, rather than compete with, its growing online channels. After all, it's not easy to get excited about a company that sells relatively-low-cost products from 1,000 expensive locations around the country. I say that noting the increasing cost of energy and hiring staff, especially under the current administration. However, with solid brand equity and strong valuation, Card Factory's one I'm watching closely. I believe it deserves attention from investors. The post What's going on with the Card Factory share price? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended WH Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
